<DOC>
	<DOCNO>NCT02472964</DOCNO>
	<brief_summary>A multicenter , double-blind , randomize , parallel-group , Phase III study efficacy safety Hercules ( Myl 1401O , Mylan Trastuzumab ) plus taxane versus Herceptin® plus taxane first line therapy patient HER2-positive metastatic breast cancer .</brief_summary>
	<brief_title>Study Efficacy Safety Myl1401O + Taxane v Herceptin©+ Taxane 1st Line , Met . Br . Ca .</brief_title>
	<detailed_description>Part 1 : A multicenter , double-blind , randomize , parallel-group , Phase III study compare efficacy safety Hercules ( Myl 1401O , Mylan Trastuzumab ) plus taxane versus Herceptin® plus taxane patient HER2+ MBC . Either docetaxel paclitaxel ( Investigator site level choice ) plan least 24 week document response therapy , disease progression , discontinuation . Disease response progression assess locally Investigator basis clinical radiographic evidence use RECIST 1.1 criterion . The primary secondary efficacy analysis perform use independently assess radiographic evidence Intent-to-Treat ( ITT ) population . The primary analysis population best ORR patient measureable disease baseline secondary endpoint , DR , responder include analysis . Part 2 : A multicenter , double-blind , parallel-group study continue compare safety immunogenicity efficacy Hercules ( Myl 1401O , Mylan Trastuzumab ) versus Herceptin® patient HER2+ MBC clinical benefit first-line combination therapy taxane . All patient least stable disease ( SD ) , continue either single agent Hercules ( Myl 1401O , Mylan Trastuzumab ) Herceptin® alone death , unacceptable toxicity disease progression . Population pharmacokinetics : During Part 1 study , Hercules ( Myl 1401O , Mylan Trastuzumab ) Herceptin® treatment arm , PK sample Cmin Cmax ( end infusion ) collect patient . A PopPK subset , sufficient sample available perform necessary analysis PopPK modeling use ass AUC , Cmax , Cmin , clearance , Vd , T1/2 various time point PopPK . Patients randomize main study sign additional consent form PopPK subset . We anticipate approximately 80 patient need enrol subset collection order obtain sufficient sample analysis . Long term survival follow-up : OS treat population determine every 3 month follow-up either 240 death 36 month , whichever occur first , observed time randomization . Exploratory evaluation : In addition , Part 1 study , blood sample collect patient assess impact soluble shed HER2/ECD PK efficacy pre-dose Cycles 1 , 3 , 5 , 7 , end treatment ( EOT ) . Additional sample ( ECD ) obtain Cycles 9 , 13 every 4 cycle thereafter , EOT end study ( EOS ) continue evaluation immunogenicity patient continue receive therapy . A blood sample obtain Cycle 1 , Day 1 , use assay development validation</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Locally recurrent MBC amenable curative surgery and/or radiation . Documentation HER2 gene amplification fluorescent situ hybridization ( FISH ) ( define ratio &gt; 2.0 ) documentation HER2overexpression immunohistochemistry ( IHC ) ( define IHC3+ , IHC2+ FISH confirmation ) base sponsoridentified central laboratory prior randomization . Archival tumor tissue sample use . Pathologically confirm breast cancer least one measurable metastatic target lesion ( base RECIST criterion , version 1.1 ) . Bone , central nervous system ( CNS ) , skin lesion , well lesion irradiate , biopsied form local intervention surgical manipulation assess nontarget lesion . Patients previously treat trastuzumab lapatinib adjuvant setting allow metastatic disease diagnose least one year last dose treatment . Prior treatment hormonal agent bisphosphonates/denosumab allow . Bisphosphonates/denosumab give simultaneously study treatment start randomization consider indication progressive disease ( PD ) . Hormonal agent must discontinue prior begin study therapy . Eastern Cooperative Oncology Group performance status ( ECOG PS ) 0 2 Serum creatinine ≤1.5 x ULN ( upper limit normal ) , Total bilirubin ≤1.0 x ULN ( &gt; 1.0 x ULN document Gilbert 's disease ) , Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) ≤2.5 x ULN , AST and/or ALT &lt; 1.5 x ULN alkaline phosphatase &gt; 2.5 x ULN , Alkaline phosphatase &gt; 2.5 x ULN ; bone metastases present liver dysfunction present . Left ventricular ejection fraction ( LVEF ) within institutional range normal measure multiple gated acquisition scan echocardiogram . Prior systemic therapy metastatic disease set . This include : chemotherapy , signal transduction inhibitor ( e.g. , lapatinib ) , HER2 target therapy ( e.g. , trastuzumab ) , investigational anticancer therapy . Prior treatment neoadjuvant adjuvant anthracyclines cumulative dose doxorubicin &gt; 400 mg/m2 , epirubicin dose &gt; 800 mg/m2 . Patients bone skin site disease . Patients skin lesion measurable CT scan MRI site measurable disease allow . Surgery radiotherapy ≤2 week precede Day 1 . Target lesion outside irradiated field patient fully recover surgery radiotherapy . Presence unstable angina history congestive heart failure accord New York Heart Association criterion , history myocardial infarction &lt; 1 year randomization , clinically significant valvular disease , serious cardiac arrhythmia require treatment , uncontrolled hypertension know pulmonary hypertension . Peripheral sensory motor neuropathy Grade 2 high accord National Cancer InstituteCommon Terminology Criteria ( NCICTC ) Version 4.03 [ 19 ] . Any cancer , include contralateral breast cancer , within 5 year prior screen exception adequately treat ductal carcinoma situ , adequately treated cervical carcinoma situ , adequately treat basal squamous cell carcinoma skin . Immunocompromized patient , include know seropositivity human immunodeficiency virus , current chronic hepatitis B and/or hepatitis C infection ( detect positive test hepatitis B surface antigen antibody hepatitis C virus confirmatory test ) . Complete listing Inc/Excl . within protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>